Literature DB >> 19813022

Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.

Jan-Ulrich Schlump1, Ertan Mayatepek, Ute Spiekerkoetter.   

Abstract

INTRODUCTION: In most countries, hereditary tyrosinemia type 1 is not included in routine newborn screening. DISCUSSION: We present the case of a female newborn with prenatal diagnosis of hereditary tyrosinemia type 1 and clear identification of this disorder by succinylacetone measurement in cord blood and peripheral blood immediately after birth. Succinylacetone was 44 micromol/L (norm <5 micromol/L) and increased within 12 h to 87.5 micromol/L.
CONCLUSION: With the high toxic potential of downstream metabolites, these data clearly point out the necessity of early nitisinone treatment to prevent symptomatic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19813022     DOI: 10.1007/s00431-009-1074-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

Review 1.  Nontransplant treatment of tyrosinemia.

Authors:  E Holme; S Lindstedt
Journal:  Clin Liver Dis       Date:  2000-11       Impact factor: 6.126

2.  Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.

Authors:  Mohamed S Rashed; Lujane Y Al-Ahaidib; Osama Y Al-Dirbashi; Mohammad Al Amoudi; Moeen M A Al-Sayed; Zuhair Rahbeeni; Zuhair Al-Hassnan; Abeer Al-Dbaas; Mohamed Al-Owain; Michelle Ni Luanaigh
Journal:  Anal Biochem       Date:  2005-04-15       Impact factor: 3.365

Review 3.  The pathophysiology and treatment of hereditary tyrosinemia type 1.

Authors:  M Grompe
Journal:  Semin Liver Dis       Date:  2001-11       Impact factor: 6.115

Review 4.  The genetic tyrosinemias.

Authors:  C Ronald Scott
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-05-15       Impact factor: 3.908

5.  Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?

Authors:  C J L Koelink; P van Hasselt; A van der Ploeg; M M van den Heuvel-Eibrink; F A Wijburg; C M A Bijleveld; F J van Spronsen
Journal:  Mol Genet Metab       Date:  2006-09-27       Impact factor: 4.797

6.  Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots.

Authors:  Coleman Turgeon; Mark J Magera; Pierre Allard; Silvia Tortorelli; Dimitar Gavrilov; Devin Oglesbee; Kimiyo Raymond; Piero Rinaldo; Dietrich Matern
Journal:  Clin Chem       Date:  2008-02-15       Impact factor: 8.327

7.  Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  S Lindstedt; E Holme; E A Lock; O Hjalmarson; B Strandvik
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

8.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

9.  Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia.

Authors:  M K Hostetter; H L Levy; H S Winter; G J Knight; J E Haddow
Journal:  N Engl J Med       Date:  1983-05-26       Impact factor: 91.245

10.  Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS.

Authors:  Osama Y Al-Dirbashi; Mohamed S Rashed; Minnie Jacob; Lujane Y Al-Ahaideb; Mohamed Al-Amoudi; Zuhair Rahbeeni; Moeen M Al-Sayed; Zuhair Al-Hassnan; Mohamed Al-Owain; Hamad Al-Zeidan
Journal:  Biomed Chromatogr       Date:  2008-11       Impact factor: 1.902

View more
  4 in total

Review 1.  Hepatorenal tyrosinemia.

Authors:  Teruo Kitagawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

Review 2.  Recommendations for the management of tyrosinaemia type 1.

Authors:  Corinne de Laet; Carlo Dionisi-Vici; James V Leonard; Patrick McKiernan; Grant Mitchell; Lidia Monti; Hélène Ogier de Baulny; Guillem Pintos-Morell; Ute Spiekerkötter
Journal:  Orphanet J Rare Dis       Date:  2013-01-11       Impact factor: 4.123

3.  Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation.

Authors:  Seyed Mohsen Dehghani; Mahmood Haghighat; Mohammad Hadi Imanieh; Hossein Karamnejad; Abdorrasoul Malekpour
Journal:  Int J Prev Med       Date:  2013-12

4.  Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia.

Authors:  Naser Honar; Nader Shakibazad; Zahra Serati Shirazi; Seyed Mohsen Dehghani; Soroor Inaloo
Journal:  Iran J Child Neurol       Date:  2017
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.